The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
Open accessAbstract
Signal transducer and activator of transcription 3 (STAT3) is a transcription factor and an attractive therapeutic target for cancer and other human diseases. Despite 20 years of persistent research efforts, targeting STAT3 has been very challenging. We report herein the structure-based discovery of potent small-molecule STAT3 degraders based upon the proteolysis targeting chimera (PROTAC) concept. We first designed SI-109 as a potent, small-molecule inhibitor of the STAT3 SH2 domain. Employing ligands for cereblon/cullin 4A E3 ligase and SI-109, we obtained a series of potent PROTAC STAT3 degraders, exemplified by SD-36. SD-36 induces rapid STAT3 degradation at low nanomolar concentrations in cells and fails to degrade other STAT proteins. SD-36 achieves nanomolar cell growth inhibitory activity in leukemia and lymphoma cell lines with high levels of phosphorylated STAT3. A single dose of SD-36 results in complete STAT3 protein degradation in xenograft tumor tissue and normal mouse tissues. SD-36 achieves complete and long-lasting tumor regression in the Molm-16 xenograft tumor model at well-tolerated dose-schedules. SD-36 is a potent, selective, and efficacious STAT3 degrader.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The application of PROTACs has afforded several advantages for targeting STAT3 over traditional inhibitors (26, 49).”
From Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer (2022) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Vilar, S., Cozza, G., & Moro, S. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608786786624 · Cited by 1,200
Flagged first, then by citations
Research works printed but not linked: 2
- Bricogne, G.; Blanc, E.; Brandl, M.; Flensburg, C.; Keller, P.; Paciorek, W.; Roversi, P.; Sharff, A.; Smart, O. S.; Vonrhein, C.; Womack, T. O. BUSTER, version, 2.10.3; Global Phasing Ltd.: Cambridge, U.K., 2017.
- Smart, O. S.; Womack, T. O.; Sharff, A.; Flensburg, C.; Keller, P.; Paciorek, W.; Vonrhein, C.; Bricogne, G. GRADE, version 1.2.13; Global Phasing Ltd.: Cambridge, U.K., 2017.
Cited by
Sorted by citations
Items 201–253 of 253
Meeting Proceedings from ICBS 2022 – Uncovering Solutions for Diseases
Syphers, J. L., Xue, L., Yi, X., Wang, R. E., & Haubrich, B. A. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00205
Cloud‐Native Rendering Platform and GPUs Aid Drug Discovery
Ross, M., Drummond, M., Westerhoff, L. M., Barbeu, X., Metwally, E., Banks‐Louie, S., Jorissen, K., Ojah, A., & Chen, R. Y. (2024) · Wiley eBooks · doi:10.1002/9783527840748.ch25
IL-21-STAT3 axis negatively regulates LAIR1 expression in B cellsPreprint
Yoshida, K., Kurata-Sato, I., Atisha‐Fregoso, Y., Aranow, C. B., & Diamond, B. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.14.632971
Wang, Y., Wang, J., Huang, S., Liu, X., Cai, Y., Wang, T., Zhao, H., Lin, X., Wang, X., & Li, P. (2025) · Scientific Reports · doi:10.1038/s41598-025-96548-9
Shi, R., Zhang, P., Chen, M., Lü, W., Xu, M., Zeng, H., He, J., Wang, Y., Lin, Y., & Liu, J. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-025-03434-0
Harnessing the power of traditional Chinese medicine for targeted protein degradation
Wu, Z., Zhu, B., Shou, Y., & Guo, H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21816-3.00011-7
Progress in the Development of PROTAC Degraders of FLT3
Fan, B., Zhou, L., Xie, Y., Huang, W., & Wang, Z. (2025) · ChemistrySelect · doi:10.1002/slct.202503917
PROTACS- targeted protein degradation as a path to precision cancer therapeutics
Gatley, H. R., Fisher, P. B., & Das, S. K. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.08.001
Recent advance in the targeted protein degradation technology for overcoming acute leukemia
Jin, X., Shi, Z., Liang, Z., Chen, J., Wang, C., Lou, Y., Cao, X., Zhu, L., Zhao, Y., Zhao, C., et al. (2026) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2026.100331
Self-citationDiscovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader
Wu, D., Zhou, H., Bai, L., Acharyya, R. K., Metwally, H., McEachern, D., Wang, M., Tošović, J., Rej, R. K., Wang, M., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03767
Self-citationHuang, H., Deng, A., Pan, F., Lu, Y., Chen, L., Cao, J., Tang, Q., Liu, Y., Wu, Y., Du, J., et al. (2026) · The Innovation · doi:10.1016/j.xinn.2026.101359
Fusion Molecules Between the STAT5b Inhibitor Stafib‐2‐CR and a Cereblon Ligand
Münzel, T., Seidenstücker, K. C., Protzel, C., Berg, A., & Berg, T. (2026) · ChemistryOpen · doi:10.1002/open.202600007
Wu, Y.-X., Wen, Y.-H., Li, Q.-H., & Zhang, L. (2026) · Translational research · doi:10.1016/j.trsl.2026.05.004
Zhang, J. Y., Li, X., Zhang, Z. Q., Wen, J., Ding, T., Zhang, Y., Deng, Z., Liao, Y., & Yu, W. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00161
Zhang, X., Chen, Q., Lei, C., Jin, D. L., Liu, H. D., Wang, Y., zhao, C., Zhi, L., & Liu, X. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00281a
Targeting conventionally intractable cancer-driving proteins: What has been achieved recently?
Xie, Q., Xu, W., Wang, Y., & Ma, X. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119102
Liu, Y., Gao, X., Xu, W., Zhang, Y., Jiang, X., Ma, X., & Wang, Y. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110243
STAT3 signaling inhibitors for cancer treatment
Akinsola, R., Xian, J., & Turkson, J. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.07.004
PROTACs in Oncology: Emerging Frontiers for Next-Generation Cancer Therapeutics
Salahuddin, S., Sharma, R., Ahsan, M. J., Mazumder, A., Rana, K., Kumar, R., & Majee, C. (2026) · Onco · doi:10.3390/onco6030048
Feng, X., Li, N., Chen, X., Cao, X., Dai, J., Xiong, S., & Yuan, Z. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118532
BindingDB Entry 50017954: PROTACs to address the challenges facing small molecule inhibitors.
BindingDB (2023) · UC San Diego · doi:10.7270/q2p55sm1
BindingDB (2021) · UC San Diego · doi:10.7270/q2nz8c6f
BindingDB Entry 50018757: PROTACs: New method to degrade transcription regulating proteins.
BindingDB (2024) · UC San Diego · doi:10.7270/q2280cvr
BindingDB Entry 50013121: Discovery of a PROTAC targeting ALK with in vivo activity.
BindingDB (2022) · UC San Diego · doi:10.7270/q25h7m0f
BindingDB Entry 50019825: Developments of PROTACs technology in immune-related diseases.
BindingDB (2024) · UC San Diego · doi:10.7270/q2cr5zrz
BindingDB (2024) · UC San Diego · doi:10.7270/q26977r0
BindingDB Entry 50015981: Discovery of a Novel Potent STAT3 Inhibitor HP590 with Dual p-Tyr
BindingDB (2023) · UC San Diego · doi:10.7270/q2rf6006
BindingDB (2023) · UC San Diego · doi:10.7270/q2t157nq
BindingDB (2022) · UC San Diego · doi:10.7270/q2z89h31
BindingDB Entry 50016515: Nucleic-Acid-Based Targeted Degradation in Drug Discovery.
BindingDB (2023) · UC San Diego · doi:10.7270/q2k35zpc
BindingDB Entry 50015597: Targeting SHP2 as a therapeutic strategy for inflammatory diseases.
BindingDB (2023) · UC San Diego · doi:10.7270/q2z60t09
BindingDB (2023) · UC San Diego · doi:10.7270/q2h9999j
BindingDB Entry 50023089: Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader.
BindingDB (2026) · UC San Diego · doi:10.7270/q2765m6w
BindingDB (2022) · UC San Diego · doi:10.7270/q2qn6bfx
BindingDB Entry 50016327: Selectivity through Targeted Protein Degradation (TPD).
BindingDB (2023) · UC San Diego · doi:10.7270/q22n568r
Metadata
- Authors
- Zhou, H., Bai, L., Xu, R., Zhao, Y., Chen, J., McEachern, D., Chinnaswamy, K., Wen, B., Dai, L., Kumar, P., Yang, C.-Y., Liu, Z., Wang, M., Liu, L., Meagher, J. L., Yi, H., Sun, D., Stuckey, J. A., & Wang, S.
- Affiliations
- University of Michigan (US)
- Corresponding author
- Wang, Shaomeng
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-11-20
- Volume
- 62
- Issue
- 24
- Pages
- 11280-11300
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- PMC
- PMC8848307
- OpenAlex
- W2990256176
- Cited by
- 233
- References
- 40
- Citations by year
- 2026: 26 · 2025: 43 · 2024: 31 · 2023: 33 · 2022: 44 · 2021: 28 · 2020: 27
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30 CA046592)
- Comprehensive Cancer Center, University of Michigan
- Oncopia Therapeutics Inc.
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- STAT3, PROTACs, small-molecule degraders, SH2 domain inhibitors, structure-based drug design, leukemia, lymphoma, xenograft tumor regression, protein degradation
- MeSH terms
- Animals, Antineoplastic Agents, Azocines, Female, Humans, Indoles, Protein Conformation, Tissue Distribution, Tumor Cells, Cultured, Drug Design, Molecular Structure, Leukemia, Myeloid, Acute, Mice, SCID, Apoptosis, Xenograft Model Antitumor Assays, Cell Proliferation, STAT3 Transcription Factor, Mice, Drug Discovery, Proteolysis, Organophosphonates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
